// App-Quantinova.ai

6000 : Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.

Researchers

Presenter

  • Steven I. Sherman

Principal Investigators

  • Ezra E.W. Cohen

  • Patrick Schoffski

  • Rossella Elisei

  • Martin Schlumberger

  • Lori J. Wirth

  • Milan Mangeshkar

  • Dana T. Aftab

  • Douglas O. Clary

  • Marcia S. Brose

Medical Centers

  • University of Pavia, Pavia, Italy

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Institut Gustave-Roussy, Villejuif, France

  • The University of Chicago Medical Center, Chicago, IL

  • University Hospital Leuven, Department of General Medical Oncology, Leuven, Belgium

  • Massachusetts General Hospital, Boston, MA

  • Exelixis, Inc, South San Francisco, CA

Locations

  • United States

  • Belgium

  • France

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Thyroid Cancer

Biomarkers

  • High affinity nerve growth factor receptor

  • Ret Proto-Oncogene

  • GTPase Nras

  • HRas Proto-Oncogene, GTPase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00704730

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved